UBS Group AG Purchases 196,445 Shares of Lakefront Biotherapeutics American Depositary Shares $LKFT

UBS Group AG lifted its position in shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) by 128.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 349,444 shares of the biotechnology company’s stock after buying an additional 196,445 shares during the quarter. UBS Group AG’s holdings in Lakefront Biotherapeutics American Depositary Shares were worth $11,427,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in LKFT. Jane Street Group LLC grew its position in shares of Lakefront Biotherapeutics American Depositary Shares by 2,245.7% during the 1st quarter. Jane Street Group LLC now owns 110,783 shares of the biotechnology company’s stock worth $2,783,000 after buying an additional 115,946 shares in the last quarter. Geode Capital Management LLC bought a new position in shares of Lakefront Biotherapeutics American Depositary Shares during the 2nd quarter worth $220,000. Jump Financial LLC bought a new position in shares of Lakefront Biotherapeutics American Depositary Shares during the 2nd quarter worth $692,000. Boothbay Fund Management LLC bought a new position in shares of Lakefront Biotherapeutics American Depositary Shares during the 2nd quarter worth $612,000. Finally, Engineers Gate Manager LP bought a new position in shares of Lakefront Biotherapeutics American Depositary Shares during the 2nd quarter worth $560,000. Institutional investors own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Price Performance

Shares of NASDAQ LKFT opened at $27.05 on Friday. The stock has a market capitalization of $1.78 billion, a P/E ratio of -19.18 and a beta of 0.25. Lakefront Biotherapeutics American Depositary Shares has a 1-year low of $26.62 and a 1-year high of $37.78. The business has a fifty day moving average price of $29.73 and a 200 day moving average price of $31.62.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last issued its quarterly earnings data on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share for the quarter. The company had revenue of $1.06 billion for the quarter. As a group, equities research analysts anticipate that Lakefront Biotherapeutics American Depositary Shares will post -6.32 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

LKFT has been the topic of a number of recent research reports. Wall Street Zen downgraded Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research report on Saturday. Royal Bank Of Canada increased their price target on Lakefront Biotherapeutics American Depositary Shares from $32.00 to $33.00 and gave the stock a “sector perform” rating in a research report on Tuesday, February 24th. Weiss Ratings raised Lakefront Biotherapeutics American Depositary Shares from a “sell (d)” rating to a “hold (c)” rating in a research report on Thursday, February 26th. Zacks Research downgraded Lakefront Biotherapeutics American Depositary Shares from a “hold” rating to a “strong sell” rating in a research report on Friday, May 8th. Finally, UBS Group reissued a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Lakefront Biotherapeutics American Depositary Shares currently has an average rating of “Hold” and a consensus target price of $36.50.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.